Suchergebnisse - "Dudnik, Elizabeth"

PubPharm (5)

1

Durvalumab after concurrent chemotherapy and high-dose radiotherapy for locally advanced non-small cell lung cancer

enthalten in: Oncoimmunology | 2021

von Landman, Y. | Jacobi, O. | Kurman, N. | +6

2

Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC) : Outcomes with immune check-point inhibitors (ICPi)

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2018

von Dudnik, E. | Bshara, E. | Grubstein, A. | +10

3

BRAF Mutant Lung Cancer : Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors

enthalten in: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 2018

von Dudnik, E. | Peled, N. | Nechushtan, H. | +17

CommentIn: J Thorac Oncol. 2018 Aug;13(8):1055-1057. - PMID 30056857

4

Not only for melanoma. Subcutaneous pseudoprogression in lung squamous-cell carcinoma treated with nivolumab : A case report

enthalten in: Medicine | 2017

von Sarfaty, M. | Moore, A. | Dudnik, E. | +1

5

Intracranial response to nivolumab in NSCLC patients with untreated or progressing CNS metastases

enthalten in: Lung cancer (Amsterdam, Netherlands) | 2016

von Dudnik, E. | Yust-Katz, S. | Nechushtan, H. | +5

1
[1]